In this cohort study of nationwide data from 2 countries, we found no statistically significant increased risk of suicide death for GLP-1 receptor agonists vs SGLT2 inhibitors used predominantly for type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.